79 related articles for article (PubMed ID: 22713591)
1. Resected duodenal gastrointestinal stromal tumour with an affected margin and exon 9 mutation: adjuvant therapy.
Salas NR; Cubillo A
Anticancer Drugs; 2012 Jun; 23 Suppl():S18-21. PubMed ID: 22713591
[TBL] [Abstract][Full Text] [Related]
2. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
Kang YK; Kang BW; Im SA; Lee JL; Park SR; Kang WK; Chang HM; Kim TW; Oh DY; Jung KH; Ryu MH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):43-51. PubMed ID: 23053257
[TBL] [Abstract][Full Text] [Related]
3. Patient with high-risk GIST not associated with c-KIT mutations: same benefit from adjuvant therapy?
Izquierdo ME; Bonastre MT
Anticancer Drugs; 2012 Jun; 23 Suppl():S7-9. PubMed ID: 22739668
[TBL] [Abstract][Full Text] [Related]
4. Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour.
Pulido EG; Riquelme A; Ballesteros J; Vaz MÁ
Anticancer Drugs; 2012 Jun; 23 Suppl():S15-7. PubMed ID: 22739666
[TBL] [Abstract][Full Text] [Related]
5. [Long-term progression-free survival after reduction surgery and postoperative low-dose imatinib administration for multiple liver metastases of duodenal gastrointestinal stromal tumor].
Nishitai R; Manaka D; Uehara M; Hamasu S; Konishi S; Sakamoto K; Yoshino K; Kanto S; Yokoyama D; Kobayashi A; Jinzai Y; Yasuhara Y
Gan To Kagaku Ryoho; 2012 Jun; 39(6):979-82. PubMed ID: 22705697
[TBL] [Abstract][Full Text] [Related]
6. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
Haller F; Detken S; Schulten HJ; Happel N; Gunawan B; Kuhlgatz J; Füzesi L
Ann Surg Oncol; 2007 Feb; 14(2):526-32. PubMed ID: 17139461
[TBL] [Abstract][Full Text] [Related]
7. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.
Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259
[No Abstract] [Full Text] [Related]
8. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.
Gronchi A
Eur J Cancer; 2013 Mar; 49(4):884-92. PubMed ID: 23206668
[TBL] [Abstract][Full Text] [Related]
9. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
10. KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
De Giorgi U
J Clin Oncol; 2007 Mar; 25(9):1146-7; author reply 1147-8. PubMed ID: 17369583
[No Abstract] [Full Text] [Related]
11. [Morphological characteristics and prognostic criteria for gastrointestinal stromal tumors].
Tsyganova IV; Anurova OA; Mazurenko NN
Arkh Patol; 2011; 73(6):37-42. PubMed ID: 22379899
[TBL] [Abstract][Full Text] [Related]
12. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
[TBL] [Abstract][Full Text] [Related]
13. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
14. Imatinib adjuvant therapy after surgical excision of gastrointestinal stromal tumour.
Prescrire Int; 2011 Feb; 20(113):38. PubMed ID: 21488587
[No Abstract] [Full Text] [Related]
15. [A case of ruptured gastrointestinal stromal tumor of the duodenum with intraabdominal bleeding].
Yamashita K; Hosaka S; Kawamoto S; Yoshida T
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2039-41. PubMed ID: 22202277
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal stromal tumour treated with neoadjuvant imatinib.
Loughrey MB; Mitchell C; Mann GB; Michael M; Waring PM
J Clin Pathol; 2005 Jul; 58(7):779-81. PubMed ID: 15976351
[TBL] [Abstract][Full Text] [Related]
17. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation.
Kobayashi M; Kuroki S; Ito K; Yasuda A; Sawada H; Ono K; Washizu T; Bonkobara M
Vet J; 2013 Oct; 198(1):271-4. PubMed ID: 23820134
[TBL] [Abstract][Full Text] [Related]
18. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.
Yeh CN; Chen TW; Tseng JH; Liu YY; Wang SY; Tsai CY; Chiang KC; Hwang TL; Jan YY; Chen MF
J Surg Oncol; 2010 Nov; 102(6):599-603. PubMed ID: 20976730
[TBL] [Abstract][Full Text] [Related]
19. [Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis].
Zhao WY; Cao H; Zhang Y; Shen ZY; Wu ZY
Zhonghua Wai Ke Za Zhi; 2009 Jun; 47(11):857-62. PubMed ID: 19961019
[TBL] [Abstract][Full Text] [Related]
20. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]